Pharmaxis Europe Patent-Cliff Exposure & CMS Drug Spending Portfolio
Pharmaxis Europe (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $250K 2024 CMS Part D & Medicaid spend, and $3,656 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 100.0% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $250K |
| 2024 Medicare Part D Spend | $126K |
| 2024 Medicaid Spend | $124K |
| California HCAI SB 17 Filings | Specialty launch notice ($3,656 intro WAC) |